Inhibikase Therapeutics Inc (IKT) - Company Value to Net Income

Corporate emblem and logo of Inhibikase (IKT)

Inhibikase Therapeutics (IKT) is led by scientists with extensive experience who effectively raise capital, although projects remain subject to standard industry risks. The company has earned recognition as the creator of a Parkinson's disease therapy that targets the root causes of the pathology. The market trend for the asset shown on this price chart reflects a P/E ratio of -2.90. The transport of biomaterials is conducted through proven international hubs and specialized services.

inhibikase.com (IKT) P/E Multiple: for the period 07/04/2022 - 11/17/2026

Analytical breakdowns for Inhibikase Therapeutics

Summary company analysis:IKT, Inhibikase Therapeutics Inc
Manufactured product of Inhibikase

Inhibikase Therapeutics (IKT) focuses on developing unique drugs to combat neurodegenerative diseases. The price-to-earnings ratio is sensitive to any changes in operating expenses related to clinical trials. This multiple determines the cost of one dollar of current earnings, reflecting market expectations for the company's future pricing power. By analyzing the company's median P/E, an investor can assess the premium paid for the potential success of the therapy.

Analysis of competing companies

Price to Earnings Ratio BIIB|P/E Multiple NBIX|Regencell (RGC) - Market Cap to Net Income Ratio|Price to Earnings Ratio axsome.com AXSM|P/E Multiple ACADIA Pharmaceuticals ACAD|XENE - Price to Earnings Ratio|Business Payback Period Viking Therapeutics Inc VKTX|Supernus Pharma (SUPN) - Price to Earnings Ratio|CPRX (Catalyst Pharmaceuticals) - Price to Earnings Ratio|DNLI (denalitherapeutics.com) - P/E Multiple|Price to Earnings Multiple HRMY (Harmony Biosciences Holdings, Inc.)|P/E Multiple BHVN|AMLX (Amylyx Pharmaceuticals Inc) - Company Value to Net Income|P/E Multiple TRVI (Trevi Pharma)|PRAX (Praxis Corp) - Market Cap to Net Income|anavex.com - P/E Multiple|Company Value to Net Income CBLL (CeriBell, Inc.)|PRTA: P/E Multiple|Price to Earnings Multiple ALEC|ANNX (Annexon Biosciences Inc.) - P/E Multiple|omeros.com - Market Cap to Net Income|Price to Earnings Ratio Neurogene (NGNE)|Business Payback Period AC Immune SA|P/E Multiple VYGR (voyagertherapeutics.com)|P/E Multiple Neumora NMRA|Scilex Holding - P/E Multiple|Market Cap to Earnings Tevogen Bio Inc.|Alpha Cognition (ACOG) - Price to Earnings Ratio|cogrx.com (CGTX) - P/E Multiple|Price to Earnings Ratio Cassava Sciences Inc|ASRT - Market Cap to Net Income Ratio|Price to Earnings Ratio Coya (COYA)|P/E Multiple VistaGen Therapeutics Inc (VTGN)|Ovid Therapeutics Inc. - Price to Earnings Ratio|Business Payback Period Acumen Pharmaceuticals (ABOS)|CervoMed Corporation - P/E Multiple|Business Payback Period alteritytherapeutics.com ATHE|CLNN: P/E Multiple|Market Cap to Earnings PepGen Corp (PEPG)|Price to Earnings Ratio Jupiter Neurosciences, Inc.|RLMD: Company Value to Net Income|P/E Multiple ANVS|Price to Earnings Ratio Grace Tx GRCE|Price to Earnings Ratio Firefly Neuroscience, Inc AIFF|KLTO: Price to Earnings Multiple|NRSN - Price to Earnings Ratio|RVPH: Price to Earnings Ratio|MTVA (MetaVia Inc.) - Price to Earnings Ratio|NeurAxis Inc. (NRXS) - P/E Multiple|Price to Earnings Ratio Helius Medical|Passage Bio, Inc. - Market Cap to Net Income|Price to Earnings Ratio NEUP (Neuphoria)|NERV - Market Cap to Earnings|P/E Multiple ATHA (athira.com)|P/E Multiple Addex Therapeutics Ltd ADXN|Alzamend Neuro, Inc. - P/E Multiple|CYCN - P/E Multiple|PTIX (Protagenic Therapeutics, Inc.) - Price to Earnings Ratio|Market Cap to Earnings Pasithea (KTTA)|Price to Earnings Ratio Cortigent|Market Cap to Earnings Avenue Therapeutics Inc. ATXI|Price to Earnings Ratio brainstorm-cell.com (BCLI)|Price to Earnings Ratio Cara Therapeutics, Inc CARA|P/E Multiple CHRO (chromocell.com)|Company Value to Net Income ELYM|Intra-Cellular Therapies Inc. - P/E Multiple|Market Cap to Earnings Longboard Pharmaceuticals Inc|Marinus (MRNS) - Price to Earnings Ratio|NKGN - Business Payback Period|Price to Earnings Ratio NeuroBo Pharmaceuticals|SAGE: Company Value to Net Income|P/E Multiple SNPX|Trevena Inc. - Price to Earnings Multiple|Price to Earnings Ratio Vigil Neuroscience, Inc. VIGL|Anew Medical, Inc. - Price to Earnings Ratio|Cerevel Therapeutics - P/E Multiple